Haemato AG

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
N/A
SEDOL
BN0SF43
CIK
N/A
www.haemato.de
LEI: 529900Q3CGRYVCW7E340
©
FIGI: BBG000M8P2G8
HAEK
Haemato AG
GICS: - · Sector: - · Sub-Sector: -
NAME
Haemato AG
ISIN
DE000A289VV1
TICKER
HAEK
MIC
XHAM
REUTERS
HAEK.DE
BLOOMBERG
HAEK GR
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Fri, 15.12.2023

Original-Research: HAEMATO AG - von GBC AG Einstufung von GBC AG zu HAEMATO AG Unternehmen: HAEMATO AG ISIN: DE000A289VV1 Anlass der Studie: Research Note Empfehlung: suspended Kursziel: suspended Letzte Ratingänderung: Analyst: Cosmin Filker; Marcel Goldmann Delisting of the HAEMATO share to take place from February 2023; price potential not yet...
Research & Analysis
Read more
Wed, 13.12.2023

Original-Research: Haemato AG - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Haemato AG Unternehmen: Haemato AG ISIN: DE000A289VV1 Anlass der Studie: Neunmonatskennzahlen Empfehlung: Not Rated seit: 13.12.2023 Kursziel: NR Kursziel auf Sicht von: - Letzte Ratingänderung: 9 September 2019 Analyst: Ellis ...
Research & Analysis
Read more
Thu, 30.11.2023

Berlin, November 30, 2023: The Management Board of HAEMATO AG ("Company"; ISIN: DE000A289VV1/ Open Market / Basic Board) has decided today, November 30, 2023, with the approval of the Supervisory Board, to terminate the inclusion of the Company's shares in the Open Market (Basic Board) on the Frankfurt Stock Exchange pursuant to Section 30 of the G...
Research & Analysis
Read more
Thu, 16.11.2023

HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in operating result:              In the first nine months of the 2023 financial year, preliminary IFRS consolidated sales rose by around 13% to EUR 212.2...
Research & Analysis
Read more
Wed, 15.11.2023

Berlin, 15. November 2023 – Due to new findings on changed market conditions, an updated validation of the profitability of the company's own botulinum toxin project was carried out.  After reviewing various options, the Executive Board decided today to terminate the cooperation with the Korean manufacturer Huons BioPharma and to discontinue the pr...
Research & Analysis
Read more
Mon, 18.09.2023

Original-Research: Haemato AG - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Haemato AG Unternehmen: Haemato AG ISIN: DE000A289VV1 Anlass der Studie: Sechsmonatsbericht Empfehlung: Kaufen seit: 18.09.2023 Kursziel: €34 Kursziel auf Sicht von: 12 Monate Letzte Ratingänderung: 9 September 2019 Analyst: El...
Research & Analysis
Read more
Thu, 14.09.2023

Original-Research: HAEMATO AG - von GBC AG Einstufung von GBC AG zu HAEMATO AG Unternehmen: HAEMATO AG ISIN: DE000A289VV1 Anlass der Studie: Research Note Empfehlung: BUY Kursziel: 32.80 EUR Kursziel auf Sicht von: 31.12.2024 Letzte Ratingänderung: Analyst: Cosmin Filker; Marcel Goldmann H1 2023: Turnover and EBIT above our expectations; forecast...
Research & Analysis
Read more
Thu, 31.08.2023

___________________________________________________________________________   HAEMATO AG publishes figures for the first half of 2023:   Increase in sales of more than 10% compared to the same period last year, further increase in EBIT margin and disproportionate increase in operating result                 In the first half of 2023, preliminar...
Research & Analysis
Read more
Fri, 14.07.2023

Original-Research: HAEMATO AG - von GBC AG Einstufung von GBC AG zu HAEMATO AG Unternehmen: HAEMATO AG ISIN: DE000A289VV1 Anlass der Studie: Research study (Anno) Empfehlung: BUY Kursziel: 30.75 EUR Kursziel auf Sicht von: 31.12.2024 Letzte Ratingänderung: Analyst: Cosmin Filker; Marcel Goldmann - Compulsory manufacturer discounts burden 'Special...
Research & Analysis
Read more
Fri, 14.07.2023

Original-Research: HAEMATO AG - von GBC AG Einstufung von GBC AG zu HAEMATO AG Unternehmen: HAEMATO AG ISIN: DE000A289VV1 Anlass der Studie: Research study (Anno) Empfehlung: BUY Kursziel: 30.75 EUR Kursziel auf Sicht von: 31.12.2024 Letzte Ratingänderung: Analyst: Cosmin Filker; Marcel Goldmann - Compulsory manufacturer discounts burden 'Special...
Research & Analysis
Read more
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements